BioCryst Pharmaceuticals BCRX Reclassification of equity awards to share-based liability

Reclassification of equity awards to share-based liability at other companies

Churchill DownsCHDN

$5.23M—

Flutter EntertainmentFLUT

$3M—

Flutter EntertainmentFLUT

-$4M-500%

Cipher Digital, Inc. CIFR

$184.25M—

CoreWeave, Inc. CRWV

$0-100%

Flutter EntertainmentFLUT

-$4M-500%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:AdjustmentsToAdditionalPaidInCapitalReclassificationOfReclassificationOfEquityAwardsToShareBasedLiability.

The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's reclassification of equity awards to share-based liability.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's reclassification of equity awards to share-based liability?: BioCryst Pharmaceuticals (BCRX) reported reclassification of equity awards to share-based liability of -$639.5K in Q4 2025.
What does reclassification of equity awards to share-based liability mean?: Represents the accounting reclassification of equity awards from permanent equity to a share-based liability due to changes in settlement terms or award characteristics. This adjustment is critical for understanding shifts in the company's balance sheet obligations related to compensation.